CureMatch Partners with SOTERIA

CureMatch, a Serra Capital III portfolio company, announced that they have partnered with SOTERIA Precision Medicine Advisory to support oncologists with personalized cancer treatment options. CureMatch is a digital health company focused on personalized medicine and combination therapy in oncology.

“SOTERIA is proud to work with CureMatch, the leader in predictive analytics for targeted combination cancer treatment,” stated Julia Civardi, Chief Executive Officer of SOTERIA. “This partnership empowers oncologists with specific treatment recommendations from a molecular basis, so patients receive truly personalized precision medicine.”

Personalized Cancer Medicine Research Spearheaded by CureMatch Co-Founders

CureMatch, a Serra Capital III portfolio company, has recently had a study published in the International Computational Intelligence Book. Co-Founders Igor F. Tsigelny, Ph.D. and Razelle Kurzrock, M.D. along with colleagues from UC San Diego and University of Bergen have authored a personalized cancer medicine study examining activation of protein complexes utilizing an innovative 4D approach.

CureMatch is a digital health company focused on personalized medicine and combination therapy in oncology. Combination therapy has been used effectively in the treatment of other diseases, such as HIV/AIDS, and is considered by many to be the future of cancer treatment. CureMatch’s decision support system guides oncologists in the selection of combinations of cancer drugs that are personalized for individual patients, based on the molecular profile of the patient’s own tumor.

Dr. Igor Tsigelny says, "Until now, only static information of mutations has been used to predict functional changes of proteins. We propose to move to the next level and add flexibility criteria for a 4D approach."

Source: https://www.prnewswire.com/news-releases/personalized-cancer-medicine-research-spearheaded-by-curematch-co-founders-300568227.html

Curematch Co-founders Study the molecular Alterations of Genes to Develop Personalized Cancer Therapy Options

CureMatch, a Serra Capital III portfolio company, has recently published a study in the journal of Cancer Biology & Therapy. CureMatch is a digital health company focused on personalized medicine and combination therapy in oncology.

The study conducted by CureMatch highlighted the role of a specific molecular mutation in eosinophilic cystitis, and how their methods might better treat this type of condition. 

Source: http://www.prnewswire.com/news-releases/curematch-co-founders-study-the-molecular-alterations-of-genes-to-develop-personalized-cancer-therapy-options-300516362.html

Serra Capital Invests in CureMatch

CureMatch, a digital health company focusing on personalized medicine and combination therapy in oncology, is Serra Capital III's 13th investment. Serra is participating in the company's Bridge to Series A round. 

"CureMatch represents a unique, breakthrough opportunity in the treatment of cancer, a disease that touches all of our lives in some way," said Steve Beck, Managing Partner at Serra Venture's San Diego office. "The company's solution resides at the intersection of precision medicine and actionable intelligence extracted from big data. We're confident that the CureMatch team is poised to lead the way in personalized cancer treatment, and we are thrilled to add them to the Serra Ventures' portfolio."

Source: http://www.biospace.com/news_story.aspx?StoryID=466700